Navigation Links
BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
Date:12/3/2007

or treatment of IgA deposition diseases, was based upon research conducted at Tufts New England Medical Center. IGAN Biosciences is based in Boston, Massachusetts. For more information, please visit http://www.iganbio.com.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: BioMarin's products and product candidates, commercialization of BioMarin's products; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the commercialization of BioMarin's products; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2006 Annual Report on Form 10-K, as amended, and the factors contained in BioMarin's reports on Form 10-Q and Form 8-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R) and Naglazyme(R) are a registered trademarks of BioMarin Pharmaceutical Inc.
Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Contact:

Investors Media

Eugenia Shen Susan Berg
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. BioMarin to Present at the BioCentury NewsMakers Conference
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
7. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
8. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
11. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
(Date:10/20/2014)... Calif. , Oct. 20, 2014 ... that the Company has signed a Notice of ... Regenerative Medicine (CIRM), effective October 1, 2014.  The ... Development payments and the release of additional grant ... CIRM grant award for clinical development of Asterias, ...
(Date:10/20/2014)... 2014 , A major pan-European ... the delivery of care has revealed changing trends in ... in the provision of healthcare services across the continent. ... United European Gastroenterology (UEG), have been announced today and ... of the burden of GI disorders across ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... 2008 at this year,s liver ... 4, SAN FRANCISCO, Oct. 27 Nonalcoholic steatohepatitis,(NASH) ... approved,medical therapy for this chronic progressive liver disease. Researchers,tested ... program. To do so, 31 overweight or obese patients ...
... Oct. 27 Carna Biosciences, Inc. ("Carna"),announced on ... Agreement with,Shanghai Universal Biotech Company ("SUBC"). Under the ... distributor of Carna,s Protein,Kinases within China., With ... in,the life sciences, major biopharmaceutical companies have now ...
... BioAtom Inc. (private) announced,today that it will present ... 28, 2008 at 2:30 PM PDT (5:30 PM EDT) ... Myron Karasik, M.B.A., C.M.C., Director of Finance, will ... Costa Mesa, CA, dedicated,to development and commercialization of Neutron ...
Cached Biology Technology:Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health 2Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company 2BioAtom Inc. To Present at BIOCOM Investor Conference 2008 2
(Date:10/14/2014)... Like discriminating thieves, prostate cancer tumors scavenge and hoard ... But such avarice may be a fatal weakness. ... to kill prostate cancer cells by delivering a trove ... the diseased cells brimming with the mineral, leaving non-cancer ... drugs already commercially available for other uses, could soon ...
(Date:10/14/2014)... (Oct. 14, 2014)—It,s been millions of years since ... team led by Ohio University scientists is breathing life ... airflow through dinosaur snouts. The research has important implications ... breathe but to enhance the sense of smell and ... animals," said Ohio University doctoral student Jason Bourke, lead ...
(Date:10/14/2014)... to produce enough food to feed the world in ... of the United Nations predicts that food production must ... a growing global population, and plants are one major ... Plants—grains, cereals, fruits, vegetables, and more—feed humans directly and ... into our knowledge of how plants work to develop ...
Breaking Biology News(10 mins):Prostate cancer's penchant for copper may be a fatal flaw 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... a celebrity living on mineral water, the glassy-winged sharpshooter ... in California, which is feverishly working to prevent the ... a surprising study published in the June 6 issue ... at The Institute for Genomic Research (TIGR), the University ...
... here have discovered a new mechanism used by cells ?and ... proteins, including some involved in cancer. , The mechanism ... made by the cell. , The study by researchers ... James Cancer Hospital and Richard J. Solove Research Institute and ...
... two frog species feared extinct has made a new ... save amphibians from a deadly fungus decimating their populations ... the two Critically Endangered frogs ?the Santa Marta harlequin ... (Atelopus nahumae) ?for the first time in 14 years ...
Cached Biology News:Surprising symbiosis: Glassy-winged sharpshooter eats with friends 2Surprising symbiosis: Glassy-winged sharpshooter eats with friends 3Scientists discover new regulating mechanism in cells 2Scientists discover new regulating mechanism in cells 3Race to halt global amphibian crisis boosted by rediscovery of endangered Colombian frogs 2Race to halt global amphibian crisis boosted by rediscovery of endangered Colombian frogs 3
... Platypus Contact Printing Kit contains choice ... with series of 100 / 200 micron ... or 200 um x 10 mm lines, ... 20, 40 or 60 nm and pitch ...
...
... 5 ml of DETACHaBEAD Mouse CD4, polyclonal ... T cells from Dynabeads Mouse CD4 (L3T4). ... cells from Dynabeads Mouse CD4 using DETACHaBEAD ... for any downstream application including flow cytometry, ...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Biology Products: